Session Chair Profile
CEO and Chairperson, N-of-One
Christine Cournoyer is Chief Executive Officer of N-of-One. Prior to joining N-of-One, she was President and Chief Operating Officer of Picis, a leading company in the healthcare IT market. Picis provided software solutions that bridge revenue cycle and clinical workflow management for high-acuity operations within hospitals, including emergency rooms, operating rooms, and critical care. Picis’ systems were installed in more than 1,800 medical centers, hospitals, and integrated delivery networks in 19 countries around the world. Ms. Cournoyer served as President and Chief Operating Officer of Lightbridge, Inc. and held senior management positions at IBM, including Vice President of Business Transformation as well as Chief Information Officer of IBM’s software group. She also served as Senior Vice President at Lotus Development. Ms. Cournoyer was named one of the “10 Most Influential Women in Technology” by Businessweek. She is currently a Corporator for Emerson Hospital and a member of both the Boston Club and the Women Corporate Directors.
Session Synopsis: Adoption of genomic testing in oncology has been slow. Even when molecular testing is done, information from tests are not always used in treatment decisions, and outcomes of targeted therapy are frequently not tracked. The molecular pathologist can help to shift this paradigm by providing useful information to the oncologist at the point of care: on-label and off-label therapeutics, access to research protocols and trials, and data to support clinical decision-making. Pathologist involvement is also critical for appropriate outcomes analysis.